Long-Term Investments - Schedule of Long-Term Investment (Details) - USD ($) |
Sep. 30, 2026 |
Dec. 31, 2025 |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-marketable Cost Method Investments, net | |||||||||||||||
| Non-marketable Cost Method Investments, net | $ 28,072 | $ 28,741 | |||||||||||||
| Equity Method Investments, net | |||||||||||||||
| Equity Method Investments, net | 2,484,137 | 1,878,465 | [1] | ||||||||||||
| Braingenesis Biotechnology Co., Ltd. [Member] | |||||||||||||||
| Non-marketable Cost Method Investments, net | |||||||||||||||
| Non-marketable Cost Method Investments, net | 6,926 | 7,014 | |||||||||||||
| Genepharm Biotech Corporation [Member] | |||||||||||||||
| Non-marketable Cost Method Investments, net | |||||||||||||||
| Non-marketable Cost Method Investments, net | 21,146 | 21,727 | |||||||||||||
| ForSeeCon Eye Corporation [Member] | |||||||||||||||
| Non-marketable Cost Method Investments, net | |||||||||||||||
| Non-marketable Cost Method Investments, net | [2] | 668,403 | |||||||||||||
| BioHopeKing Corporation [Member] | |||||||||||||||
| Non-marketable Cost Method Investments, net | |||||||||||||||
| Non-marketable Cost Method Investments, net | |||||||||||||||
| BioFirst Corporation [Member] | |||||||||||||||
| Equity Method Investments, net | |||||||||||||||
| Equity Method Investments, net | [3] | 1,240,990 | 1,298,038 | ||||||||||||
| Rgene Corporation [Member] | |||||||||||||||
| Equity Method Investments, net | |||||||||||||||
| Equity Method Investments, net | [4] | 546,672 | 551,686 | ||||||||||||
| BioLite Japan K.K. (BioLite JP) [Member] | |||||||||||||||
| Equity Method Investments, net | |||||||||||||||
| Equity Method Investments, net | [5] | ||||||||||||||
| OncoX BioPharma, Inc. [Member] | |||||||||||||||
| Equity Method Investments, net | |||||||||||||||
| Equity Method Investments, net | [6] | ||||||||||||||
| |||||||||||||||